Societe D'etudes Scientifiques Et Industrielles De L'ile-de-france

Synthelabo

Laboratoires Delagrange (synthelabo)

Laboratoires Delagrange Div. Societe D'applications Pharmacodynamiques

Laboratoires Delagrange Societe D'application Pharmacodynamiques

Laboratoires Delagrange Societe D'applications Pharmacodnymiques

Societe D'etudes Scientifiques Et Industrielle De L'ile-d-france

Jean-Paul Schmitt

Jacques Acher

Jean-Claude Monier

Brenda Costall

Robert J Naylor

Renee Gardaix-Luthereau

Pascal George

Mireille Sevrin

Jocelyne Roy

Danielle De Peretti

Gardaix-Luthereau Renee

Compound corresponding to the formula: ##STR1## in which X represents one or more of hydrogen, halogen, alkyl, trifluoromethyl, alkoxy, alkylthio, methylsulphonyl, cyano, ethoxycarbonyl, aminocarbonyl and carboxy, Y represents one or more of hydrogen, halogens, alkyl, trifluoromethyl, methoxy and trifluoromethoxy, R.sub.1 represents hydrogen, alkyl, phenylmethyl, 2-phenylethyl, acetyl or alkoxycarbonyl, R.sub.2 and R.sub.3 each represent hydrogen, alkyl which is optionally substituted, prop-2-enyl, prop-2-ynyl, phenyl, 1-(phenylmethyl)piperidin-4-yl, or 1-[(cyclohexen-1-yl)methyl]piperidin-4-yl, or alternatively R.sub.2 and R.sub.3 form, with the nitrogen atom carrying them, an optionally substituted heterocycle. These compounds are useful as hypnotic, anxiolytic and anticonvulsant agents.

9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-imidazolyl)-ami no]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Method of providing anxiolytic and antipsychotic treatment

The present invention relates to the use of substituted benzamides of formula (1): ##STR1## in which: A is linear or branched C.sub.1 -C.sub.3 alkyl; allyl or diethylaminoethyl;

Method of increasing gastrointestinal motility with substituted

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-immidazolyl)-am ino]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

The invention relates to the use of benzamide derivatives of the formula: ##STR1## in which: A is a diethylaminoethyl group or a group of the formula II: ##STR2## where R is a C.sub.1 -C.sub.3 alkyl, allyl, cyclopropylmethyl or cyclohexenylmethyl group,

Method of treating disorders of cognitive function with substituted

The present invention relates to the application of substituted benzamides of formula (I): ##STR1## in which: A is diethylaminoethyl, 1-ethyl-2-pyrrolidinylmethyl or 1-allyl-2-pyrrolidinylmethyl;

Method of providing anxiolytic and antipsychotic treatment with

New substituted benzamides have the general formula: ##STR1## their optical isomers and their physiologically acceptable salts. The compounds are used as activators of the central nervous system.

Novel benzamides, intermediates and process for the preparation and

New substituted benzamides have the general formula: ##STR1## A=alkyl, alkenyl, diethylaminoethyl or ##STR2## R.sub.1, R.sub.2 =H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl; R.sub.3, R.sub.4, R.sub.5, R.sub.6 =hydrogen or C.sub.1 -C.sub.6 alkyl;

Growing community of inventors

Arpajon, France

Jean-Paul Schmitt